Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas.

Ga-pentixafor, a ligand of CXCR4 (CXC chemokine receptor type 4), has been reported as a potential PET tracer to evaluate a variety of pathological entities. We report intense Ga-pentixafor activity on PET/CT in 2 patients in the histopathologically confirmed adrenal adenomas, which were the cause of their Conn syndrome.

[1]  A. Buck,et al.  Imaging Inflammation in Atherosclerosis with CXCR4-Directed 68Ga-Pentixafor PET/CT: Correlation with 18F-FDG PET/CT , 2019, The Journal of Nuclear Medicine.

[2]  A. Buck,et al.  CXCR4-Directed Imaging in Solid Tumors , 2019, Front. Oncol..

[3]  A. Buck,et al.  Chemokine Receptor 4 Expression in Primary Sjögren's Syndrome. , 2018, Clinical nuclear medicine.

[4]  Z. Özkan,et al.  Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT. , 2018, Clinical nuclear medicine.

[5]  Jun Feng,et al.  Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia. , 2018, Clinical nuclear medicine.

[6]  Q. Pan,et al.  Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT. , 2018, Clinical nuclear medicine.

[7]  A. Buck,et al.  Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma , 2018, Hypertension.

[8]  T. Derlin,et al.  Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden , 2017, The Journal of Nuclear Medicine.

[9]  W. Staab,et al.  68Ga-Pentixafor PET/CT Imaging of Chemokine Receptor CXCR4 in Chronic Infection of the Bone: First Insights , 2017, The Journal of Nuclear Medicine.

[10]  J. Slotta-Huspenina,et al.  Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities , 2017, EJNMMI Research.

[11]  Michael Lassmann,et al.  Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach , 2017, Theranostics.

[12]  R. Kapoor,et al.  68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Johannes Ettl,et al.  First Experience with Chemokine Receptor CXCR4–Targeted PET Imaging of Patients with Solid Cancers , 2016, The Journal of Nuclear Medicine.

[14]  T. Derlin,et al.  Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG. , 2016, Clinical nuclear medicine.

[15]  S. Nekolla,et al.  Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI , 2016, Journal of Nuclear Cardiology.

[16]  T. Derlin,et al.  Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. , 2015, JACC. Cardiovascular imaging.

[17]  A. Buck,et al.  Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients , 2017, Clinical nuclear medicine.

[18]  Saskia,et al.  Targeting CXCR 4 ( CXC Chemokine Receptor Type 4 ) for Molecular Imaging of Aldosterone-Producing Adenoma , 2022 .